The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or via email CSmith@GabrailCancerCenter.com.
A Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects with Active Non-Hematological Cancers
An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refactory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Return to Clinical Trials at GCC
